Vor Biopharma INC 8-K filings

Vor Biopharma Inc. reports the resignation of Director Andrew Levin and the appointment of David Zaccardelli to its Board.

Vor Biopharma stockholders approved an amended 2021 Equity Incentive Plan and elected two directors at the 2026 Annual Meeting.

Vor Biopharma announces NMPA conditional approval for IgA nephropathy and approval for Sjögren's disease for telitacicept in China, developed by collaborator RemeGen.

Vor Bio announced a $75 million private placement led by TCGX to accelerate clinical development of telitacicept for autoimmune diseases.

Vor Biopharma Inc. announced preliminary cash of $450 million for year-end 2025 and provided updates on its telitacicept autoimmune programs, including global Phase 3 trials for Myasthenia Gravis and Sjögren's Disease.

VOR Biopharma Inc. announced the departure of its Chief Development Officer, Dr. Qing Zuraw, effective December 31, 2025, with a separation agreement detailing severance and a 12-month non-compete.

Vor Biopharma Inc. announced a $150 million private placement to fund its clinical pipeline, alongside key appointments to its Board of Directors.

Vor Biopharma Inc. announced a stock option repricing for approximately 5.2 million shares, reducing the exercise price to $8.18 per share to retain and motivate employees.

Vor Biopharma Inc. announced a public offering of 10 million common shares at $10.00 each, expecting to raise approximately $93.7 million to fund clinical development and extend its cash runway into Q2 2027.

Vor Biopharma Inc. announced the appointment of Dr. Jeremy Sokolove as Chief Medical Officer and amended the employment agreement for its Chief Development Officer, Dr. Qing Zuraw.

Vor Biopharma Inc. announced positive 48-week Phase 3 clinical trial data from China for telitacicept in primary Sjögren's disease, demonstrating significant efficacy and a favorable safety profile.

Vor Biopharma Inc. will implement a 1-for-20 reverse stock split effective September 18, 2025, to consolidate its common stock.

Vor Biopharma Inc. presented compelling clinical data for its dual BAFF/APRIL inhibitor, telitacicept, in Myasthenia Gravis and Primary Sjögren's Disease, alongside a robust financial position and significant global expansion plans.

Vor Biopharma Inc. announced the resignation of three directors and the appointment of Sarah Reed, a nominee of RA Capital Management, to its Board of Directors.

Vor Biopharma Inc. stockholders approved an expanded equity incentive plan, the issuance of common stock for warrants, and a potential reverse stock split, alongside the filing of a new at-the-market offering for up to $119.7 million.

Vor Biopharma Inc. announced significant leadership enhancements, including the appointment of Qing Zuraw as Chief Development Officer and the addition of Michel Detheux and Alexander Cumbo to its Board of Directors, aiming to accelerate clinical development and strategic growth.

Vor Biopharma Inc. announced the appointment of Sandesh Mahatme, a seasoned biopharmaceutical executive with extensive experience in capital markets and operations, as its new Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective July 9, 2025.

Vor Biopharma Inc. announced a transformative license agreement for telitacicept with RemeGen, a $175 million private placement, and the appointment of Jean-Paul Kress as its new Chief Executive Officer and Chairman of the Board, alongside the resignation of Robert Ang and termination of a significant lease.

Vor Biopharma Inc. announced that its stockholders approved an amendment to significantly increase the number of authorized common shares from 400 million to 800 million, alongside the election of two Class I directors and the ratification of its independent auditor.

Vor Biopharma Inc. designates its CEO, Robert Ang, as the principal financial and accounting officer, effective May 19, 2025.

Vor Biopharma announces a strategic shift to explore alternatives, including a potential sale or merger, while winding down clinical and manufacturing operations and reducing its workforce by 95%.

Vor Biopharma Inc. received a notice from Nasdaq for non-compliance with the minimum bid price requirement, as its common stock price remained below $1.00 for 30 consecutive business days.

Eyal C. Attar, M.D., Chief Medical Officer of Vor Biopharma, has resigned effective April 18, 2025, to pursue a new opportunity.

Vor Biopharma's board of directors approved a stock option repricing to incentivize employee retention and motivation.

Vor Biopharma has appointed Erez Kalir, a seasoned life sciences and technology investor, to its Board of Directors, following a recent private investment led by Reid Hoffman.

Vor Biopharma has announced a $55.6 million private placement to fund clinical development and extend its cash runway through key data releases in 2025.

Vor Biopharma reported updated clinical data showing improved relapse-free survival for AML patients treated with trem-cel followed by Mylotarg, along with supportive feedback from the FDA on their registrational trial design.

Vor Biopharma has appointed Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective September 30, 2024.

Vor Biopharma reports promising clinical data from its Phase 1/2 trial of trem-cel combined with Mylotarg, demonstrating reliable engraftment, shielding, and early signs of patient benefit, along with the introduction of a new preclinical asset, VADC45.

Vor Biopharma has been notified by Nasdaq that it is not in compliance with listing rules due to its stock price falling below $1.00 for 30 consecutive days.